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taken from the essential drug list and the database of drugs prices. Standard 
of treatment of CP developed by Ministry of Health of the Russian Federation 
was used for calculation of medical care costs. Costs of adverse events were 
calculated basing on Russian clinical guidelines and database of drugs prices. 
Disability pensions and disable child care were taken from the Russian Pension 
Fund database. The cost of orthopedic surgeries was calculated on the basis of RF 
Government program of state guarantees of free rendering to citizens of medi-
cal care. Results: Usage of AbobotulinumtoxinA treatment+standard therapy 
in whole population of SCP patients in Russia will result in 79,585 RUB/1,473 
$ economy compared with OnabotulinumtoxinA+standard therapy, 131,178 
RUB/2,429 $ economy compared with standard therapy per one patient for 2 
years. This cost reduction is mainly attributed to decrease of number of ortho-
pedic surgeries to the better efficacy of this BTA drug. ConClusions: Inclusion 
of abobotulinumtoxinA+standard therapy appears to be a cost saving treatment 
option in the management of spastic cerebral palsy in the Russian Federation com-
pared with onabotulinumtoxinA+standard therapy and standard therapy solely.
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objeCtives: PEGIFN beta-1a is the first pegylated interferon beta-1a administered 
subcutaneously every two weeks, indicated for the therapy of relapsing remit-
ting multiple sclerosis (RRMS). The objective of this analysis was to estimate the 
potential economic impact following due of the introduction of PEGIFN beta-1a in 
Italy. Methods: The analysis was conducted with a three-year time horizon with 
the support of a decision-analytic model adopting the perspective of the Italian 
National Healthcare Service (NHS). Healthcare costs sustained by the Italian NHS for 
the management of the RRMS population (drug treatment, monitoring, relapse man-
agement, adverse event management) were calculated over 3 years and compared 
for two scenarios: i) The current scenario where only interferon beta and glatiramer 
acetate are RRMS patients available and ii) An alternative scenario after the intro-
duction of PEGIFN beta-1a. The RRMS population was estimated to be approximately 
35,500, 37,500 and 39,500 patients at Year 1, 2 and 3 respectively, based on published 
epidemiology literature and market data. The efficacy of treatments was simulated 
as reduction of relapse rates and was derived from a mixed treatment comparison. 
Unit costs were based on Italian 2015 prices and tariffs, and the published literature. 
A one-way sensitivity analysis was developed. Results: According to current price 
and reimbursement conditions established by the Italian NHS, the introduction 
of PEGIFNb-1a will result in cost savings. This model found that PEGIFN beta- 1a 
would provide in related of treating RRMS patients an estimated annual costs of 
€ 318,800,000, € 336,100,000 and € 353,600,000 in Year 1, 2, and 3 respectively compared 
to the costs of the current scenario of € 319,200,000, € 337,200,00 and € 355,200,000 
in Year 1, 2, and 3, respectively. The cumulative budget reduction over the three 
year period was € 3,100,000 (an approximate 0.3% savings). ConClusions: The 
adoption of PEGIFN beta-1a for the treatment of RRMS is economically sustainable 
by the Italian NHS.
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bACkgRound: Epileptic seizures are associated with significantly impaired quality 
life, excessive healthcare resource use and thus high costs. According to published 
sources based on clinical data new anti-epileptic add-on therapy options for refrac-
tory patients with partial-onset seizures with or without secondary generalisation, 
such as lacosamide and perampanel, has achieved greater efficacy by responder 
rates (better control of the seizures) and seizure freedom than placebo being equally 
effective between each other. objeCtives: to estimate the budgetary impact of the 
introduction of 2 types of adjunctive treatment in adult patients with refractory 
partial epilepsy (RPE) - lacosamide and perampanel added to standard treatment, 
and to forecast this impact over the following three years in Kaliningrad region of 
Russian Federation. Methods: The budget impact model has been developed for 
the Russian Federation regions. Efficacy data used to assess the resource consump-
tion was taken from randomized clinical trials and meta-analysis. The demographic 
parameters and the partial epilepsy incidence were calculated based on the official 
statistic surveillance system data for the regions. Resource use was estimated by 
expert survey. Drug and other medical costs were calculated on the basis of regis-
tered vital and essential drug list prices and regional tariffs. Results: Introduction 
of lacosamide to clinical practice (as add-on anti-epileptic treatment) compared to 
perampanel with equal market shares of 10%, 20% and 30% leads to average budget 
savings of healthcare system in Kaliningrad region, which amounted to: € 27 081.25 
in first year, € 43 746.63 in the second year, € 78 119.00 in the third year, for treat-
ing 131, 140 and 149 patients with RPE, respectively. ConClusions: The analysis 
showed that introduction of adjunctive therapy with lacosamide in the market for 
the treatment of patients with PRE compared to perampanel could save budget 
funds by reducing drug costs in Russian Federation regions.
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SC IFNβ -1a is projected to avoid 28, 10, and 10 additional escalations to second-line 
therapy compared with IM IFNβ -1a, IFNβ -1b, and GA, respectively, resulting in cost sav-
ings of £685,391, £231,021, and £231,021. Results were most sensitive to each therapy’s 
risk of relapse at 2 years. ConClusions: Among newly-diagnosed RRMS patients, 
treatment with SC IFNβ -1a is projected to avoid more relapses and escalations to 
second-line therapy compared with IM IFNβ -1a, IFNβ -1b, and GA over 2 years. These 
projected cost offsets within the UK may be applicable to other payer environments.
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objeCtives: Botulinum toxins (BT) are a valuable treatment option for patients 
with post-stroke upper-limb spasticity (PS-ULS), which affects 33,000 patients in 
the UK. Xeomin (incobotulinum toxin A) and Botox (onabotulinum toxin A) are 
two BTs licensed for the treatment of PS-ULS. The treatment costs for Xeomin and 
Botox will depend on their real-world usage. Methods: Dosing data were col-
lected for patients switching from Botox to Xeomin treatment between 2007–2012 
from the Mid-Yorkshire Hospitals Trust (MYHT) UK (comprised of 3 centres). The 
dose of each BT received per limb at each visit was extracted from the dataset for 
7 visits (the 3 visits before and 4 visits after switching). List prices from the British 
National Formulary for different vial sizes were applied to these data to generate a 
simple budget impact model. Results: 89 patients (127 limbs) were identified who 
switched treatment from Botox to Xeomin, of which 49 patients (54 limbs) fulfilled 
study criteria. The average dose of Xeomin was 147.2 units per limb and Botox was 
156.9 units per limb. Due to the lower list price of Xeomin and the comparable 
dosing frequency between Botox and Xeomin (average time between injections 
was 154 days for Botox and 156 days for Xeomin), switching resulted in an aver-
age cost-saving of £26 per limb, per visit. This represented an estimated overall 
annual saving of £3,263. Accounting for sharing of vials reduced the estimated 
saving slightly (£3,166 overall). The real-world saving made by MYHT was greater 
than this as this analysis included upper-limb spasticity only, therefore a number 
of limbs did not fit study criteria and were not included in the estimated annual 
savings. ConClusions: Real-world dosing for Xeomin and Botox was comparable. 
Based on the lower list price of Xeomin, this indicated potential cost savings for 
switching from Botox to Xeomin.
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objeCtives: To compare direct medical costs for patients with relapsing-remit-
ting multiple sclerosis (RRMS) treated with subcutaneous (sc) IFNβ 1a 44mcg three 
times weekly (TIW) versus other interferon-beta (IFNβ ) therapies across endpoints 
comprising the “no evidence of disease activity” (NEDA) measure. Methods: A 
decision-analytic model was developed using comparative efficacy data sourced 
from a network meta-analysis (NMA) of IFNβ therapies: scIFNβ 1a 44mcg TIW, 
scIFNβ 1b 250mcg every other day, intramuscular (im) IFNβ 1a 30mcg once weekly, 
and pegylated (peg) IFNβ 1a 125mcg every two weeks. The number of patients experi-
encing NEDA-related endpoints (relapse, new MRI activity, or disability progression) 
for each therapy was determined using risk ratios derived from odds ratios (ORs) vs. 
placebo (pairwise analysis) or vs. other IFNβ therapies (NMA analysis). The model 
followed 1,000 patients with RRMS over 2 years. Costs were sourced from the litera-
ture. One-way sensitivity analyses (OWSAs) were performed to test the robustness 
of the results. Results: Only medical costs were assessed, thus observed cost-
offsets meant fewer patients experienced NEDA-related endpoints. For scIFNβ 1a 
44mcg vs. pegIFNβ 1a, results from the pairwise analysis projected cost-offsets of 
$893,652 (relapse) and $252,219 (MRI); results from the NMA also projected cost-
offsets of $578,174 (relapse), $15,628 (disability), and $105,667 (MRI). For scIFNβ 1a 
44mcg vs. imIFNβ 1a, results from the pairwise analysis projected cost-offsets of 
$755,737 (relapse) and $239,926 (MRI); results from the NMA also projected cost-
offsets of $525,511 (relapse), $118,716 (disability), and $110,435 (MRI). For scIFNβ 1a 
44mcg vs. scIFNβ 1b, results from the pairwise analysis projected cost-offsets of 
$84,826 (relapse) and $32,435 (disability); results from the NMA also projected a 
cost-offset of $35,948 (disability). OWSAs confirmed substantial cost-offsets for the 
comparisons examined. ConClusions: The results of this decision-analytic model 
suggests that scIFNβ 1a 44mcg provides substantial cost-offsets versus other IFNβ 
treatments across NEDA-related endpoints.
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objeCtives: To conduct budget impact analysis of abobotulinumtoxinA+standard 
therapy, onabotulinumtoxinA+standard therapy and standard therapy solely 
in patients with spastic cerebral palsy (SCP) in Russia for 2-year period. Total 
number of patients with spastic cerebral palsy in Russia is 55 899. Methods: 
A budget impact model was developed in Excel 2013 to simulate the costs of 
spastic cerebral palsy therapy in the Russian Federation. The following costs 
were taken into account: the costs of pharmacotherapy, inpatient and outpatient, 
sanatorium-resort care, costs of adverse events, casting, orthopedic surgeons, 
disability pensions, disable child care benefit. Costs of pharmacotherapy were 
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objeCtives: Studies have shown that the consumption of drugs in ATC subgroup 
“other antiepileptics” is increasing and that they are more expensive than the older 
antiepileptic drugs. Little information on the prescribing and cost of these drugs is 
available in South Africa. The primary aim was to analyse the prescribing patterns 
of ATC subgroup N03AX (other antiepileptics) with emphasis on cost and the role 
of generic prescribing. Methods: A retrospective drug utilisation study was con-
ducted on a South African community pharmacy dispensing database for 2013. All 
products for ATC subgroup N03AX were extracted and analysed. Results: A total 
of 233 596 products were dispensed to 50 603 patients at an average cost of R209.64. 
Two-thirds of patients (65.06%) were between 30 and 59 years of age, and 55.35% 
of patients were female. Five different active ingredients were prescribed, namely 
gabapentin (8.55% of products in group N03AX), lamotrigine (52.20%), levetiracetam 
(3.39%), pregabalin (21.60%) and topiramate (14.25%). No prescriptions for vigaba-
trin were dispensed. Pregabalin and gabapentin were prescribed to a slightly older 
patient population, possibly due to their use also in neuropathic pain. Lamotrigine 
had the most branded generics on the South African market (originator and six 
branded generics). As expected, lamotrigine also had the lowest average cost per 
product (R179.83). Levetiracetam had the lowest prescribing frequency, but also 
the highest average cost per product (R452.82). Levetiracetam was the only product 
available as a solution. Pregabalin was the only active ingredient with no generic 
equivalents (average cost of R245.19). The number of products per month stayed 
relatively constant, except for lamotrigine which showed a slight increase in pre-
scribing frequency during the year. ConClusions: Newer antiepileptics are gener-
ally better tolerated than the standard drugs, often with equivalent efficacy, but are 
more expensive. This study provided a baseline for further studies to be conducted.
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objeCtives: To examine the treatment patterns and direct medical costs of patients 
with multiple sclerosis (MS) treated with prolonged-release (PR) fampridine tablets 
(dalfampridine extended-release in the US) 12 months pre- and post-initiation of 
treatment. Methods: A retrospective analysis of the Health Risk Institute research 
database, which contains healthcare and prescription claims of approximately 80 
German health insurances, was conducted. Patients with MS who initiated treat-
ment with PR-fampridine (index date) were identified between January 1, 2011 and 
December 31, 2012. Eligible patients were required to be continuously insured dur-
ing 12 months pre- and post-index date and to have at least one PR-fampridine 
prescription in the 4th quarter after the index date. Pre- vs. post-index costs and 
utilization of inpatient stays were compared related to MS and prescription medi-
cations using each patient as their own control. Results: A total of 478 patients 
were eligible and included in this analysis. The mean (SD) age was 50.1 (9.5) years, 
54.0% of patients had no concomitant disease modifying therapy and 64.9% were 
female at baseline. A significant decline (all p< 0.001) in the mean (SD) number 
of MS-related inpatient stays -0.20 (1.06); mean (SD) total length of stay -1.02 
(8.84); and proportion of patients with an inpatient stay pre-index vs. post-index 
period (31.4% vs. 23.6%) was observed. A significant (p< 0.001) decrease in mean 
(SD) inpatient costs for the pre- vs. post-index periods was also observed: € 1,718 
(3,406) vs. € 1,305 (3,844), respectively, or € -413 (3,211). An increase in the costs of 
MS-related prescription medications in the post-period was attributed to the cost of 
PR-fampridine. ConClusions: Treatment with PR-fampridine resulted in a reduc-
tion of inpatient hospital stays, number of days, and MS-related costs within one 
year in German MS patients. Further research is needed to understand how improve-
ment in walking may reduce direct MS-related outpatient utilization and costs.
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objeCtives: The aim of this study is to estimate the cost of illness (COI) from a 
societal perspective of all multiple sclerosis (MS) patients of working ages in Sweden, 
and to explore the distribution of the COI of MS. Methods: We conducted a pop-
ulation-based study among the 14,077 individuals 20-64 years of age with MS who 
were identified in nationwide registers covering healthcare use or social insurance 
benefits. Costs during 2010 were estimated from resource use identified in registers, 
including direct costs (i.e., drug use, outpatient and inpatient care) and indirect costs 
(i.e., productivity loss due to sick leave and disability pension, estimated using the 
human capital method). Resource use for which MS was the main diagnosis was 
also identified. Results: In total, the COI of all individuals aged 20-64 years with 
MS in Sweden was SEK 3950 million in 2010 (≈EUR 414 million). Indirect costs con-
tributed to 75% of the COI. MS was the main diagnosis for resource use attributing 
to 38% of the healthcare costs and 67% of the indirect costs. The distribution of 
costs was skewed, with one-fifth of MS patients contributing to half of the total COI 
and one-fifth of MS patients who had no measured costs during 2010. A large part 
of the prescription drug costs (≈15% of the COI) occurred in a patient group that 
otherwise contributed to less than 30% of the COI. ConClusions: The distribution 
of costs was skewed among MS patients, and the cost distribution differed between 
overall COI and prescription drug costs, which will affect cost estimates in studies 
of MS when population-based samples are unavailable. Further studies on factors 
affecting the distribution of different cost components among MS patients are thus 
objeCtives: The aim of this study was to evaluate the budget impact of modern 
anti-Parkinson drugs in monotherapy early Parkinson’s disease in the Russian 
Federation. Methods: For analysis of market data regarding Parkinson’s dis-
ease (PD) treatment products we used IMS Health Russia database (2014). The 
target population was newly diagnosed PD patients over 60 years in the early 
clinical stages. The time horizon for this analysis was taken for 1-year period. 
Comparison drugs: pramipexole ER, piribedil CR, ropinirole ER and rasagiline. In 
the analysis we have only taken the cost of anti-Parkinson therapy and a possible 
change of therapy due to ineffectiveness into account assumed that the cost for 
correction of adverse reactions is a patient cost. The cost of switching therapy 
due to ineffectiveness was calculated based on the assumption that the prescrip-
tion probability for each comparator is 33.3%. Effectiveness of the anti-Parkinson 
drugs was evaluated as the percentage of patients who responded to treatment. 
Discounting was not conducted because the time horizon of the analysis did not 
exceed 1 year. Results: As a result of calculations the cost of the 1st year therapy 
with piribedil CR, pramipexole ER, ropinirole ER and rasagiline was 28,822, 20,810, 
57,449 and 54,332 rubles respectively. The cost of the 1st year of therapy taking into 
account the change of therapy due to ineffectiveness is: 32,799, 26,300, 53,218 and 
51,266 rubles per patient per year for piribedil CR, pramipexole ER, ropinirole ER 
and rasagiline respectively. ConClusions: BIA showed that the largest budget 
savings was achieved in the treatment of PD with pramipexole ER. Pramipexole 
ER in monotherapy resulted in cost savings worth 6,499 rub. (20%) vs. piribedil CR, 
26,918 rub. (51%) vs. ropinirole ER and 24,966 rub. (49%) vs. rasagiline per patient 
per a year of therapy.
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objeCtives: Available DMTs in multiple sclerosis (MS) differ regarding monitoring 
requirements. The aim of this research was to assess monitoring cost differences 
for glatiramer acetate (GA) and other DMTs in the UK, France, Spain, Germany, Italy, 
and US. Methods: Monitoring requirements for GA, teriflunomide, interferon beta-
1a, fingolimod (FG), natalizumab, dimethyl fumarate (DF), and alemtuzumab were 
obtained from EMA and FDA labels. Required monitoring unit costs were obtained 
from publicly available sources for each country in scope (EU5 and US). An analysis 
with different time horizons (1, 3, and 5 years) was conducted to determine relative 
monitoring costs. Results: Common monitoring tests include liver and thyroid 
function, blood cell count, magnetic resonance imaging (MRI), and serum creatinine. 
Based on 1-year data, DMTs with the two lowest and highest monitoring costs in the 
US were DF ($396), GA ($426), natalizumab ($1183), alemtuzumab ($1316); in Spain GA 
(118€ ), DF ($152), natalizumab (502€ ), alemtuzumab (998€ ); in Italy DF (47€ ), GA (61€ ), 
natalizumab (213€ ), alemtuzumab (348€ ); in France GA (98€ ), DF (102€ ), FG (323€ ), 
alemtuzumab (819€ ); in UK DF (£317), GA (£354), FG (£560), alemtuzumab (£662); in 
Germany GA (58€ ), DF (59€ ), natalizumab (222€ ), alemtuzumab (474€ ). Physician 
consultation fees are an important cost driver, especially in the UK and US where the 
cost of a specialist visit is higher versus other countries. In France, Spain, Germany, 
and Italy, visits to specialists are less expensive; thus, test costs have a bigger impact 
on the overall monitoring costs. These trends were confirmed by 3-year and 5-year 
data. ConClusions: Monitoring cost of GA is low compared to biologic drugs that 
require either expensive annual examinations such as MRI (natalizumab) or fre-
quent laboratory tests (alemtuzumab). Differences in monitoring costs should be 
included in the overall economic evaluation of DMTs in MS.
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objeCtives: The objective of this study was to evaluate health care costs over time 
in patients diagnosed with vascular dementia (VD) who had a prior diagnosis of 
Alzheimer’s disease (AD) compared with similar patients with no prior diagnosis 
of AD in patients in Italy. Methods: A cohort of patients whose most recent 
diagnostic records for dementia indicated presence of VD was identified from 
administrative databases of a sample of Italian Local Health Units. VD patients 
were required to have no indication for other dementia types between their earli-
est indication of cognitive decline or earliest VD diagnosis (index date) and their 
most recent VD diagnoses and to have continuous data visibility for ≥ 6 months 
prior to the index date. The cohort was then categorised based on diagnosis of AD 
prior to their first confirmed VD diagnosis, and followed for up to 3 years post-
index. Patients with prior AD were matched to similar patients with no prior AD 
using propensity score methods. Annual healthcare costs were calculated for the 
two cohorts. Results: Of the 2652 VD patients, who were primarily identified 
in a hospital setting, 103 (4%) had prior AD diagnoses. All 103 patients with prior 
AD were successfully matched (ratio 1:5) for the cost analysis. Patients with prior 
AD misdiagnosis had higher annual healthcare costs over the follow up period 
compared to those patients without prior diagnosis. For patients with 3 years of 
follow-up average health care costs (95% Confidence limits) per patient with prior 
AD diagnosis were € 10,899(7410, 14387), € 5256(2578, 7754), € 4409 (2090, 6727) in 
years 1, 2 and 3 respectively, compared to € 8196(6652, 9741), € 3404(2177, 4632) and 
€ 2770(1958, 3582) in the no prior AD cohort. ConClusions: This retrospective 
analysis suggests that possible misdiagnosis of AD among Italian patients with 
VD results in greater health care costs.
